Pharmaceutical Accountability Foundation

We are working in the public interest to hold pharmaceutical companies accountable. Your endorsement can make a difference.

Show your support for the Pharmaceutical Accountability Foundation

The Pharmaceutical Accountability Foundation acts in the public interest and strives to make overpriced drugs more affordable through legal actions that hold pharmaceutical companies accountable.

Complaint against Leadiant

For example, in 2018, Farma ter Verantwoording filed a complaint with the ACM about the excessive prices that pharmaceutical company Leadiant was charging for a pre-existing orphan drug. The ACM fined Leadiant €19.5 million for this in 2021.

Proceedings against AbbVie

In December 2021, the Pharmaceutical Accountability Foundation held one of the world’s largest biopharma companies, AbbVie, liable for the excessive (unfair) prices it charged for the drug Humira during the period it enjoyed patent protection.

Help us continue our work by making a donation and/or stay informed through our newsletter.

Help us continue our work by making a donation. Stay informed with our newsletter.

Statement of Support

I think it is unfair that pharmaceutical companies make excessive profits on their drug or technology that cause healthcare to be displaced elsewhere in society, such as in the above described Leadiant and AbbVie cases.

-and/or-

I think pharmaceutical companies should align their practices with human rights principles such as the human right to health and access to health care.

-and/or-

I believe that pharmaceutical companies (should) have a (legally enforceable) duty of care towards patients and society.

-and/or-

Patients and society suffer from abuse of the EU Orphan Drug regulation and pharma piracy (when pharmaceutical companies buy up drugs and hike up prices excessively without valid reason). I believe that pharmaceutical companies should not be able to abuse intellectual property rights or other market monopolies.

-and/or-

I have my own reason, which I would like to specify as a comment with my signature.

I hereby express my sympathy and want to contribute to achieving the goal of the foundation, which is to make medicines and medical technologies affordable and accessible to everyone.

Learn more about the Foundation’s mission.

See the data processing and conditions for signing.

!

Current Supporters

Organisations

client-image
client-image
client-image
client-image
client-image
client-image
client-image
client-image
client-image

Interested in your organisation being added here? Contact us at info@farmaterverantwoording.nl. 

Committee of Recommendation

Our Committee of Recommendation exists of inspiring people and (academic) experts affiliated with the field of (access to) medicines and healthcare.

Em. Prof. Dr. André Knottnerus

Physician epidemiologist, former chair of the Health Council, and emeritus professor of family medicine at Maastricht University. He publishes regularly on the need to treat essential medicines and vaccines as global public goods.

Prisca Zwanikken, MD, M.Sc.CH, PhD

Senior public health expert, involved in capacity building of training and educational institutions in low- and middle-income countries. A long-time member of HAI, she is also involved in teaching Rational Drug Use

Em. Prof. Dr. Gerrit van der Wal, MD

Advisor and supervisor health care, former GP, emeritus professor of public health and former Inspector-General/CMO Netherlands.

Prof. Dr. Pim van Gool

Professor of Neurology at Public and Occupational Health Amsterdam UMC and former chair of the Health Council of the Netherlands.

Em. Prof. Dr. F.M. Haaijer-Ruskamp

Emertitus Professor Drug Use UMCG. Expertise on rational prescribing and drug use, with attention to both individual (e.g., decisions) and macro-level influences, such as policy, price, and pharma industry.

Gilles de Wildt

Associate Clinical Professor Global Health at University of Birmingham (UK) and General Practitioner (Primary care Physician).

Chris Oomen

Entrepeneur, pharmacist and former chair of the board of DSW health insurance organisation.

Godelieve van Heteren, MB, MD

Senior international health, governance and Performance Based Financing consultant. Former member Dutch Parliament (PvdA).

Individuals

Latest Signatures
176 Annemarie van de Ruit Netherlands social worker
175Anonymous Turkey Artist Stop rediculous prices of medicines and new patents on existing medicines.
174 Ben Emans Netherlands burger
173 Carlos Leónidas Leiva Belgium Technology Transfer and IPM Expert
172 rita klaucke Netherlands professional artist
171 Enzio Bakker Netherlands Docent Betaalbare medicijnen zijn een mensenrecht
170Anonymous Netherlands MD, educator
169 John Doe Netherlands -
168 Irene van Meer Netherlands Huisarts in opleiding
167 Liliya Eugenevna Ziganshina Russian Federation RMANPO
166 yvonne klein rouweler Netherlands klassiek homeopaat
165 Erna Burks Netherlands General practitionar
164Anonymous Germany Student
163Anonymous Netherlands Huisarts
162 Gijs Reedeker Netherlands nvt
161 Ilja Camping Netherlands N.v.t.
160 Douwe Enserink Netherlands Chiropractor
159 Petra ter avest Netherlands Huisarts
158 Jan Oosting Netherlands Burger
157 Piet de Nennie Netherlands No function and No organisation Farmaceutische bedrijven zijn criminele organisaties.
156 Iris te Stroete Netherlands Aios reumatologie
155 Marco Bosch Netherlands Gepensioneerd Ik weinig toe te voegen aan waar Stichting Farma ter Verantwoording voor staat!
154 Petra Van Eif Netherlands The Dutch Tea Lady
153 Amanda Kluveld Netherlands Historicus Eerst dit goed regelen voordat ouderen en chronisch zieken onder druk worden gezet omdat ze zoveel zouden kosten en de gezondheidszorg belasten.
152Anonymous Netherlands Student
151 Wouter Jong Netherlands Business Developer
150 Anja De Respinis - de Jong Netherlands Familydoctor
149 Mieke Heikoop Netherlands Huisarts
148 Frank Van den Bergh Netherlands Doctor clinical Biochemistry
147 Bas de Klerk Netherlands student Oneerlijke misbruik van een machtspositie
146Anonymous Netherlands Health logistics consultant Ik vind dat het huidige patent systeem "unfit for purpose" is, omdat het op teveel manieren misbruikt kan worden om meer geld te verdienen, ten koste van publieke gezondheidszorg. Handelen in oude patenten moet aan banden worden gelegd, niet alleen in de EU, maar overall en de TRIPS agreement moet worden gerespecteerd, óók door de Verenigde Staten!
145Anonymous Netherlands DA
144 Aad van den Berg Netherlands UMCG
143 Jan Mulder Netherlands none
142 Pieter Bots Netherlands Huisarts
141Anonymous Netherlands Huisarts in opleiding
140 Kim Julie Muijres Netherlands Fine Art Clinic High profits are inhumane
139 Lucas Kroft Netherlands Gp
138 Mariella Stamato Netherlands Praktijkverpleegkundige huisartsenpraktijken de Amstel in Uithoorn
137Anonymous Netherlands Huisarts
136 Jeroen Paar Netherlands SEH-arts, Haaglanden MC
135Anonymous Netherlands Huisarts
134 Hans veen van der Netherlands Huisarts
133Anonymous Netherlands praktijkverpleegkundige
132 C. J. Vos Netherlands Huisarts Belang van integriteit
131 Peter Lucas Netherlands professor Universiteir Twente Het maken van excessieve winsten van Farma moeten worden aangepakt.
130 Wijnand Rutgers Netherlands Neuroloog
129 Albert ter Braak Netherlands radioloog
128 Abram Rutgers Netherlands gepensioneerd huisart Zorg moet voor iedereen toegankelijk en betaalbaar zijn!
127Anonymous Netherlands sportsphysician
126 Rob Baatenburg de jong Netherlands Department Chair ErasmusMC
125 Sandra Rutgers Netherlands arts np
124 Mia de Haan Netherlands Arts
123Anonymous Netherlands ARTS
122 Nelly Welling Netherlands Aios ouderengeneeskunde Farma moet zijn verantwoordelijkheid nemen en niet voor de grote winsten gaan.
121Anonymous Netherlands Huisarts
120 Lizanne Kremer Netherlands Aios
119 Christine Walravens Netherlands Mka arts
118Anonymous Netherlands KNO-arts Eens, redelijke winst is meer dan voldoende
117 Pascale Heuts Netherlands Huisarts
116 Gea van der Zee Netherlands Huisarts Zorggroep Almere
115 marjan lebon Netherlands psychosomatisch arts n.p.
114 Willem Peelen Netherlands Kinderarts n.p.
113 Pieter Stokkers Netherlands MDL-ARTS
112 Germa Joppe Netherlands Huisarts
111Anonymous Netherlands arts
110 GIJM ter Braak Netherlands Psychiater
109Anonymous Netherlands Gynecologist OLVG hospital Amsterdam
108 Floris Vanmolkot Netherlands Internist MUMC
107 Albertus Jellema Netherlands Retired
106 Lyke Westland Netherlands Voormalig Consultatiebureauarts, jeugd
105 paul van t pad bosch Netherlands rheumatologist
104 Paul den Brave Netherlands Forensisch arts in opleiding, FARR Rotterdam
103Anonymous Belgium Huisarts
102 Joost Mertens Netherlands Psychiater
101Anonymous Netherlands Apotheker, Apotheek Barentsen
100Anonymous Netherlands Olvg
99Anonymous Netherlands Arts
98Anonymous Netherlands Jurist
97 Anna Putten Netherlands Huisartsen praktijk Korte Akkeren
96 Anne Emans Netherlands jeugdarts
95Anonymous Netherlands Student
94Anonymous Netherlands Landelijk Centrum Stressmanagement
93 Kees Blase Netherlands HartFocus
92 Mariejo Stassen Netherlands Gepensioneerd Geen overmatige winst over de rug van zieken
91 Reinout Koning Netherlands particulier gerechtigheid!
90 ruud platenburg Netherlands patient
89 Fiskelien van Goor Netherlands Zelfstandige I totally support the Stuchting’s goal, for the benefit of all of mankind
88 Bjm Jansen Netherlands Geen
87 Joost Verbrugge Netherlands Product Owner bij Rainforest Alliance Eens met standpunten - nav artikel in Volkskran
86 Joke Verveer Netherlands gepensioneerd
85Anonymous Netherlands IT Specialist Ik vind dat farmaceutische bedrijven een (juridisch afdwingbare) zorgplicht (moeten) hebben ten opzichte van patiënten en de samenleving.
84 Jacobus Stiekema Botswana Retired physician / internist Graag deelname en mijn support
83 Joanne de Lange Netherlands myself
82Anonymous Netherlands burger
81Anonymous Netherlands N.v.t. Bezorgde burger
80 Anneke Durlinger Netherlands tjoys NLP training & coaching De buitensporige winsten getuigen niet van moreel leiderschap. Hier lijden patienten en de samenleving onder.
79 Alex Dröge Netherlands CZ Zorgverzekeraar
78 FROUKJE Brouwer Netherlands Retired
77Anonymous Netherlands ondernemer
76Anonymous Netherlands Ruim, director Rechtvaardigheid en gelijkwaardigheid
75 Roelof ten Doesschate Netherlands Psychiater n.p.
74Anonymous Netherlands - Winsten op medicijnen moeten fair zijn en moeten het algemeen belang dienen en moeten niet het doel hebben om organisaties en/of individuen te verrijken
73Anonymous Netherlands Prive Ik heb 5 jaar enorme pijn gehad. Mijn behandelaars hebben Humira die 5 jaar uitgesteld omdat het TE duur was. Hierdoor heb ik fysiek onherstelbare schade opgelopen aan mijn gewrichten. Is mijn jeugd afgepakt. Heb niet kunnen studeren. Indien er een normale prijs was gevraagd. Was het medicijn WEL toegankelijk geweest in een eerder stadium. Had ik niet op mijn 25ste gesloopte gewrichten gehad.
72 Suzanne Onderwater Netherlands Verpleegkundig Specialist Oncologie Antoni van Leeuwenhoek zkhs Amsterdam Winst maken ten koste van zorg en met publiek geld moet niet kunnen
71Anonymous Netherlands Implementatieconsultant
70 Mark Burgmans Netherlands Interventieradioloog
69 Arend Stemerding Netherlands economic research
68 Frederic van Kleef Netherlands Managing director Aletta Jacobs School of Public Health
67 Wilbert Bannenberg Netherlands chair, PAF test
66 Rosalind Turkie France researcher
65 Peter Turkie France General Practitioner I see that there is less than optimal care in society when a pharmaceutical company charges an unreasonably high price for a drug or medical technology
64 Robert Kikkert Netherlands Seasoned Regulatory Affairs Professional
63 Ini Huijts Netherlands onafhankelijk public health consultant
62 Arnold Daems France oud tandarts
61 Paul Vellekoop Netherlands ambtenaar
60Anonymous Netherlands Bewindvoerder
59 Aad de Groot Netherlands Voorzitter RvB DSW Zorgverzekeraar Ja ik onderteken uit naam van DSW
58 Chris Oomen Netherlands Zelfstandig ondernemer, apotheker, voormalig voorzitter RvB DSW Zorgverzekeraar
57 Iris Wichers Netherlands Huisarts
56 Diederik Aarendonk Netherlands European Forum for Primary Care Competition in Health Care provision leads to more health inequity
55Anonymous Netherlands Apotheker
54 Marielle Bemelmans Netherlands Director People worldwide have the right to health. Pharmaceutical companies have human rights obligations.
53 Pieter van den Hombergh Netherlands EFPC EFPC WG aks for action on AMR
52 Jacob Hamel United Kingdom Public Health Arts & Consultant (tropics) alle mensen hebben recht op best mogelijk toegang tot medicijnen en gezondheidszorg
51 Gilles de Wildt United Kingdom Associate Clinical Professor, Global Health
50 Jan Borg Netherlands Public Health Consultant
49 Jennifer Sellin Netherlands Assistant Professor international human rights law, Faculty of Law, Maastricht University
48 Kees Godschalk Netherlands particulier
47 Trecy Hemedi Netherlands Student at Vrije University
46 Frans M Lindelauf Netherlands oud-ziekenhuisapotheker
45 Paul Jonas Netherlands Arts econometrist Leids Universitair Medisch Centrum Medicijnen zijn een maatschappelijk goed,dat niet in particuliere handen hoort.
44 Prisca Zwanikken Netherlands Public Health Consultant
43 Francisco Rossi Colombia Senior Adviser I see the negative consequences in society because pharmaceutical companies do not act in line with human rights principles, such as the right to health care and access to medicine.
42 Elina Hemminki Finland LSV I see that there is less than optimal care in society when a pharmaceutical company charges an unreasonably high price for a drug or medical technology.
41 Lucas van der Hoeven Netherlands psycholoog / journalist
40 Ewout Kattouw Netherlands Voorzitter stichtjng PILL
39 Marta Medina Denmark Public Health Consultant
38 Kirsten Myhr Norway MScPharm, MPH Because high prices is a barrier to access
37 Krisantha Weerasuriya Sri Lanka Professor Emeritus of Pharmacology, University of Colombo Those of us in LMICs have been campaigning for this from 1990s. Welcome ! I sign as an individual.
36Anonymous Netherlands UHD
35 Staffan Svensson Sweden GP, Clinical Pharmacologist, Hjällbo Vårdcentral Närhälsan
34 Mohga Kamal-Yanni United Kingdom Freelance
33 Patrick Durisch Switzerland Health Policy Expert, Public Eye I see the negative consequences in society because pharmaceutical companies do not act in line with human rights principles, such as the right to health care and access to medicine.
32 Chinu Srinivasan India Mngmnt, Low Cost Standard Therapeutics It is important work you are doing
31 Adriane Fugh-Berman United States Director, PharmedOut
30 Ellen Shaffer United States Co-Director, Center for Policy Analysis on Trade and Health (CPATH)
29 Arta Denina Latvia Doctoer
28 Eleni Alevritou Greece Vice president of Consumer Association the Quality of Life-EKPIZO
27 Monique De Koning Netherlands Publlic Health officer Oneigenlijk gebruik van monopolies leidt tot hoge zorgkosten en schaadt de toegankelijkheid van zorg in Nederland en wereldwijd. Gebruik makend van kennis uit publiek gefinancierde wetenschap, vindt extreme verrijking plaats. Ook het klimaat wordt geschaad in dit ongelijkheid versterkende systeem.
26 Joel Lexchin Canada Professor Emeritus, York University Access to affordable medicines is a human right.
25 Irene Schipper Netherlands Onderzoeker SOMO Misbruik van monopolies als het om medidijnen gaat moet niet door overheden gefaciliteerd worden
24Anonymous Kenya Supply Chain Specialist, Independent consultant I work in the humanitarian sector and seeing inflated cost of pharmaceuticals rendering families bankrupt and living without hope is painful
23 Kaitlin Mara Aland Islands No hello
22 Lisa Konickx Netherlands Apotheker Steunt bij deze
21Anonymous Netherlands Docent, HU -
20 Evianne van der Kruk Netherlands Openbaar apotheker bij apotheek Stelle en docent farmacotherapie aan UU Medicijnen zouden voor iedereen beschikbaar en betaalbaar moeten zijn.
19 Adriaan Mutsaers Netherlands Zzp -
18 Eric van der Borg Netherlands ApotheekVrij Eerlijk duurt het langst!
17 Johan van Luijn Netherlands Apotheker niet-praktiserend hoge prijzen ondermijnen de solidariteit van ons zorgstelsel en maakt dat wereldwijd vele geen toegang kunnen krijgen tot goede zorg. Farmaceutische bedrijven maken oneigenlijk gebruik van hun monopolie posities en zetten daarmee de betaalbaarheid van de zorg onder druk
16 Hans van Commenee Netherlands openbaar apotheker/Leeuwen Apotheek Een medicijn tegen asociaal gedrag?
15Anonymous Netherlands apotheker Hopelijk heeft het effect!
14 Gabriel Montalvo Netherlands UvA There was a presentation at the Uva where I attend school at.
13 chiara merlo Netherlands student I care about the cause
12 Jan Pieter de Jong Netherlands Apotheker (Spangen Rdam) Doorgaan!
11 Guus Eskens Netherlands Bestuurslid Healthnet TPO Doorzetten ! Belangrijke campagne !
10Anonymous Netherlands Ziekenhuisapotheker Eindelijk, go get them!
9 Herma Lobik Netherlands Apotheek van der Laan veel succes!
8Anonymous Netherlands Apotheker np
7 Tessa Jager Switzerland IHEID MA in International Law, former GCCP coordinator Good luck!
6 Richard van Slobbe Netherlands Apotheker/consultant Put the pressure on!
5Anonymous Finland Secretary of the Board, PAF Sign the statement of support!
4 Wilbert Bannenberg Netherlands public health consultant prima aktie!
3 Rosalind Turkie France RESEARCHER access to meds is a human rights issue!
2Anonymous Netherlands Medical writer, PPG Medicijnen moeten toegankelijk en betaalbaar zijn voor iedereen. Geen misbruik van machtspositie!
1 Kaitlin Mara Switzerland Researcher/Writer toegang tot medicijnen voor iedereen!

Data processing and conditions for signing

Clicking “hide name from public” means signing anonymously. Your name will not be displayed on the website. If necessary, it will only be shown confidentially before a court. Other entered data are visible.

The content of the above statement of support may be amended in the future to reflect the current state of affairs. If you want to be kept informed about this or if you want to change your signature, send an email to projectcoordinator@farmaterverantwoording.nl

We store your data in a database in accordance with AVG guidelines.